In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Seismic Shifts As Torrential Rain Dampens JPM Jamboree

Executive Summary

Drug pricing, diversity and US tax reform dominated discussions at JP Morgan. Deals announced at the conference didn't spark much excitement, but attendees were confident that the biopharma sector will still get capital market support.

Advertisement

Related Content

Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?
Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?
In Vivo's 2017 Deals Of The Year: The Winners Are…
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond
Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan
New Payment And Financing Models For Curative Regenerative Medicines

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV005271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel